Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
Rhea-AI Summary
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for August 11, 2025, after market close.
The company will release its quarterly Letter to Stockholders on its website and host a conference call with a live webcast on August 12, 2025, at 8:00 a.m. Eastern Time. Investors can access the webcast through Harrow's website, and telephone participants must register in advance to receive dial-in details.
Positive
- None.
Negative
- None.
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 12, 2025
NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 12, 2025, to discuss the results and provide a business update.
Conference Call Information
Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, for accessing the call.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
Contact:
Mike Biega
VP of Investor Relations & Communications
mbiega@harrowinc.com
617-913-8890
FAQ
When will Harrow (HROW) report Q2 2025 earnings?
How can investors access Harrow's Q2 2025 earnings call?
Where can I find Harrow's Q2 2025 Letter to Stockholders?
How long will Harrow's Q2 2025 earnings webcast replay be available?
